Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.

Similar presentations


Presentation on theme: "Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon."— Presentation transcript:

1 Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon University, France

2 Previous work by Piot et al. (NEJM 2008) Objective: determine whether cyclosporine A can reduce infarct size in STEMI patients Direct stenting Coronary artery occlusionReperfusion t0t0 t -10 min Cyclosporine A (or saline) (2.5 mg/kg, IV bolus) Day 1-3 CK / TnI release Day 5 MRI Infarct size STEMI < 12 hrs PCI treatment LAD TIMI flow grade 0-1 No visible collaterals

3 0 1000 2000 3000 4000 5000 6000 CK release Adm. 4h 8h 12h 16h20h 24h 30h 36h42h48h54h 60h 66h72h Control CsA (UI/L) 0 50 100 150 200 250 Control CsA Adm. 4h 8h 12h 16h 20h 24h 30h 36h42h48h 54h 60h 66h72h TnI release 0 1.4.10 5 10305070 ACS (%) AUC (arbitrary units) 1.2.10 5 1.0.10 5 0.8.10 5 0.6.10 5 0.4.10 5 0.2.10 5 control CsA CK release 0 0204060 1.2.10 5 1.0.10 5 0.8.10 5 0.6.10 5 0.4.10 5 0.2.10 5 AUC (arbitrary units) TnI release Reduction of cardiac enzymes release by cyclosporine A Piot et al. NEJM 2008

4 0 control cyclosporine area of hyperenhancement (g) 10 20 30 40 50 60 70 120 * MRI infarct size (day 5) Piot et al. NEJM 2008;359:473-81

5 Mewton et al. J Am Coll Cardiol 2010;55:1200–5

6 Rationale CsA can reduce infarct size in STEMI patients. It is therefore expected that this protective effect may be associated with a reduced adverse LV remodeling However, experimental evidence indicates that CsA, via anti-hypertrophic mechanisms, may favor an adverse remodeling response of the LV after STEMI We then assessed LV volumes and wall thickness by MRI at 5 days and 6 months after AMI in a population of patients that had received CsA as an adjunct to PCI revascularization

7 PCI Coronary artery occlusionReperfusion t0t0 t -10 min Cyclosporine A or saline Day 5 MRI 6 Month MRI Follow up CMR at 6 months post-MI Mewton et al. JACC 2010

8 * Control Cyclosporine

9

10 Mewton et al. (JACC 2010) Cyclosporine in acute myocardial infarction

11 PCI Coronary artery occlusionReperfusion t0t0 t -10 min Cyclosporine A Day 5 MRI 6 Month MRI Follow up CMR at 6 months post-MI Mewton et al. J Am Coll Cardiol 2010;55:1200–5

12 There was a significant correlation between left ventricular end-diastolic volume (LVEDV) and infarct size at 6 months (r2=0.40; p<0.05) in the whole group of patients

13 There was a significant correlation between left ventricular end-systolic volume (LVESV) and infarct size at 6 months (r2=0.66; p<0.05) in the whole group of patients

14 There was a significant correlation between left ventricular ejection fraction (LVEF) and infarct size at 6 months (r2=0.72; p<0.05) in both groups of patients

15 * MRI at 6 months after cyclosporine-treated MI * Mewton et al. (JACC 2010)

16 Conclusion Cyclosporine used at the moment of acute myocardial infarction reperfusion reduces infarct size and does not have a detrimental effect of LV remodeling. These results obtained from a limited population of patients must be confirmed by large-scale trials

17 Michel OVIZE, MD, PhD


Download ppt "Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon."

Similar presentations


Ads by Google